<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708171</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2020-081-2</org_study_id>
    <nct_id>NCT04708171</nct_id>
  </id_info>
  <brief_title>The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections</brief_title>
  <acronym>PROGRAM</acronym>
  <official_title>The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as an international, multicenter prospective cohort study. Patients&#xD;
      with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be&#xD;
      selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a&#xD;
      craniotomy where the resection boundaries for motor or language functions will be identified&#xD;
      by the &quot;awake&quot; mapping technique (awake craniotomy, AC); 2) a craniotomy where the resection&#xD;
      boundaries for motor functions will be identified by &quot;asleep&quot; mapping techniques (MEPs,&#xD;
      SSEPs, continuous dynamic mapping); 3) a craniotomy where the resection boundaries will not&#xD;
      be identified by any mapping technique (&quot;no mapping group&quot;). All patients will receive&#xD;
      follow-up according to standard practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological morbidity</measure>
    <time_frame>Between baseline and 6 weeks/3 months/6 months postoperatively</time_frame>
    <description>NIHSS deterioration of 1 point or more as compared to baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of resection</measure>
    <time_frame>Assessed within 72 hours on postoperative MRI scan</time_frame>
    <description>Resection percentage as assessed by an independent neuroradiologist on MRI contrast images with volumetric analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Between surgery and 12 months postoperatively</time_frame>
    <description>Progression-free survival (PFS) defined as time from diagnosis to disease progression (occurrence of a new tumour lesion with a volume greater than 0.175 cm³, or an increase in residual tumour volume of more than 25%) or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Between surgery and 12 months postoperatively</time_frame>
    <description>Overall survival (OS) defined as time from diagnosis to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onco-functional outcome</measure>
    <time_frame>Between baseline and 6 weeks/3 months/6 months postoperatively</time_frame>
    <description>2D coordinate based on extent of resection (or residual tumor volume) on the x-axis and NIHSS score on the y-axis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of Serious Adverse Events (SAEs)</measure>
    <time_frame>Between surgery and 6 weeks postoperatively</time_frame>
    <description>Infections, intracerebral bleeding, epilepsy, aphasia, paresis/paralysis in arms or/and legs (this is not an exhaustive list).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual tumor volume</measure>
    <time_frame>Assessed within 72 hours on postoperative MRI scan</time_frame>
    <description>Postoperative tumor volume in mm3 as assessed by an independent neuroradiologist on MRI contrast images with volumetric analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRC deterioration (for motor gliomas)</measure>
    <time_frame>Between baseline and 6 weeks/3 months/6 months postoperatively</time_frame>
    <description>MRC deterioration of 1 point or more as compared to baseline value.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">453</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Awake mapping under local anesthesia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asleep mapping under general anesthesia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Resection under general anesthesia without mapping</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Awake mapping under local anesthesia</intervention_name>
    <description>During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.</description>
    <arm_group_label>Awake mapping under local anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Asleep mapping under general anesthesia</intervention_name>
    <description>During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.</description>
    <arm_group_label>Asleep mapping under general anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection under general anesthesia without mapping</intervention_name>
    <description>During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.</description>
    <arm_group_label>Resection under general anesthesia without mapping</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with primary or recurrent glioblastoma (GBM).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤ 90 years&#xD;
&#xD;
          2. Tumor diagnosed as GBM on MRI as assessed by the neurosurgeon&#xD;
&#xD;
          3. Tumors situated in or near eloquent areas; motor cortex, sensory cortex, subcortical&#xD;
             pyramidal tract, speech areas or visual areas as indicated on MRI (Sawaya Grading II&#xD;
             and II)&#xD;
&#xD;
          4. The tumor is suitable for resection (according to neurosurgeon)&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumors of the cerebellum, brain stem or midline&#xD;
&#xD;
          2. Multifocal contrast enhancing lesions&#xD;
&#xD;
          3. Medical reasons precluding MRI (e.g. pacemaker)&#xD;
&#xD;
          4. Inability to give written informed consent (e.g. because of severe language barrier)&#xD;
&#xD;
          5. Second primary malignancy within the past 5 years with the exception of adequately&#xD;
             treated in situ carcinoma of any organ or basal cell carcinoma of the skin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasper Gerritsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasper Gerritsen, MD</last_name>
    <phone>+31629119553</phone>
    <email>j.gerritsen@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnaud Vincent, MD PhD</last_name>
    <email>a.vincent@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof. Steven De Vleeschouwer, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Haaglanden</name>
      <address>
        <city>The Hague</city>
        <state>Zuid-Holland</state>
        <zip>2261 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Jasper Gerritsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

